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Much effort has been devoted to the identification of immunologically important factors in
tuberculous pleurisy (TBP) and malignant pleurisy (MP) to improve the differential
diagnosis of the two major causes of lymphocyte-dominant pleurisy. This study evaluated
the immunoreactivity and potential diagnostic utility of both host (cytokines and
chemokines) and pathogen (mycobacterial proteins) factors in pleural effusions. Effusion
samples were collected from 41 patients with MP caused by lung cancer and from 81
patients with TBP. The concentrations of nine cytokines and chemokines (interleukin
(IL)-12 p40, interferon (IFN)-g, tumor necrosis factor (TNF)-a, IL-6, IL-10, CXCL8/IL-8,
CXCL10/IP-10, CCL3/MIP-1a, and CCL4/MIP-1b) and antibody responses (IgG, IgM, and
IgA) against five Mycobacterium tuberculosis antigens (early secreted antigenic target
(ESAT)-6, 30-kDa, MTB12, 38-kDa, and a heparin-binding hemagglutinin (HBHA)) were
determined in pleural fluids using enzyme-linked immunosorbent assays (ELISA). In the
logistic regression, IFN-g (odds ratio, 7.178; 95% confidence interval (CI), 2.258–22.817;Elsevier Ltd. All rights reserved.
tbc, Mycobacterium tuberculosis; TBP, tuberculous pleurisy; MP, malignant pleurisy; IFN, interferon;
ukin; ELISA, enzyme-linked immunosorbent assay; CFP, culture filtrate protein.
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Immunoreactivities in Tuberculous Pleurisy 281p ¼ 0.001), IL-12 p40 (odds ratio, 11.037; 95% CI, 3.38–36.037; po0.001), and IL-6 (odds
ratio, 3.295; 95% CI, 1.147–9.463; p ¼ 0.027) were found to be statistically significant
cytokines predicting tuberculous from malignant effusions. Although IgG responses to all of
the M. tuberculosis antigens tested were significantly higher in effusions from TBP
(po0.001) compared with those from MP, the logistic regression showed IgG levels for
ESAT-6 and MTB12 to be statistically significant for differentiation of TBP from MP. HBHA
showed the highest sensitivity of IgM antibody responses in TBP in comparison with other
antigens. These data indicate that selected mycobacterial antigens (ESAT-6 and MTB12)
and cytokine markers (IFN-g, IL-12p40, and IL-6) provide useful information for
differentiating tuberculous and malignant effusions in clinical practice.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Tuberculosis (TB) remains the major infectious cause of
death worldwide. Approximately one-third of the world’s
population is infected with its causal agent, Mycobacterium
tuberculosis (M. tbc).1 Tuberculous pleurisy (TBP) occurs in
15% of disease cases and is regarded as a positive response to
M. tbc infection.2 TBP is characterized by an extensive
inflammatory exudate in the pleural space, probably
developing from the rupture of a caseous focus in the lung.3
In particular, TBP is important in the era of HIV infection,
because TBP is more commonly encountered in clinical
practice.4
Tuberculosis pleurisy and malignant pleurisy (MP) are two
major causes of lymphocyte-dominant pleurisy. Differentiat-
ing between TBP and MP is a critical clinical problem.
Conventional methods such as the direct examination of
pleural fluid using Ziehl–Neelsen staining, pleural fluid
culture, and pleural biopsy have limitations and are not
always helpful in making a diagnosis. Microscopy findings of
the pleural fluid are rarely positive (o5%).5 Although not
perfect, culture or biopsy is widely considered the standard
of diagnosis.5 However, pleural biopsy is invasive, operator
dependent, and technically difficult, particularly in chil-
dren.6 To improve the differential diagnosis of TBP and MP,
specific mycobacterial antigens and host factors such as
cytokines and chemokines should be characterized to
determine the occurrence and significance of the corre-
sponding immune responses.
The pleural levels of a number of biomarkers have been
proposed as aids in the differential diagnosis of TBP and non-
TBP. Numerous cytokines and chemokines are induced during
the development of a pleural effusion. Interferon (IFN)-g, a
cytokine produced by CD4+ T lymphocytes, increases the
phagocytic activity for mycobacteria; the local production
of IFN-g is increased in TBP.7,8 The pro-inflammatory
cytokine tumor necrosis factor (TNF)-a level is significantly
higher in TBP than in MP,9 whereas the level of interleukin
(IL)-1b does not differ significantly.10 The levels of TNF-a, IL-
6, and CCL2/MCP-1 are significantly higher in TBP than in
parapneumonic effusions. In addition, several CC- or CXC-
chemokines are increased in TBP patients compared with
non-TBP patients.11 However, more information from com-
parative studies is needed to improve the usefulness of
cytokines and chemokines in differentiating between TBP
and MP.A variety of mycobacterial antigens, such as proteins and
lipids, can be used as alternative diagnostic tests based on
serology.12–15 Proteins secreted by M. tbc are reported to
possess strong antigenicity, as they are principal T-cell
stimulators, which induce the production of cytokines,
activate macrophages, and mediate the cutaneous de-
layed-type hypersensitivity reaction.16 We examined five
proteins secreted by M. tbc available in our laboratory. Four
of them (the early secreted antigenic target (ESAT)-6,12
30-kDa,13 38-kDa,14 and heparin-binding hemagglutinin
(HBHA)15 antigens of M. tbc) are reported to induce humoral
immune responses in active pulmonary TB or TBP infection.
The MTB12 protein strongly induced proinflammatory
cytokine production by peripheral blood mononuclear cells
from active TB patients.13 However, little is known of the
roles of these five antigens in the local immune responses
during TBP or MP infection.
This study compared the differences in the profiles of nine
cytokines and chemokines (IFN-g, TNF-a, IL-6, IL-12p40, IL-
10, CXCL8/IL-8, CXCL10/IP-10, CCL3/MIP-1a, and CCL4/MIP-
1b) and in the antibody responses against five mycobacterial
antigens [ESAT-6, 30-kDa, MTB12, 38-kDa, and HBHA anti-
gens of M. tbc] between pleural effusions from MP (n ¼ 41)
and TBP (n ¼ 81) patients, using an enzyme-linked immu-
nosorbent assay (ELISA). To our knowledge, this is the first
study to characterize the usefulness of a variety of
biomarkers (both in host and pathogen) at the same time,
in differentiating between TBP and MP. We show that
mycobacterial antigens (HBHA for IgM, ESAT-6 and MTB12
for IgG) and cytokine levels (IFN-g, IL-12p40, and IL-6)
could differentiate tuberculous from malignant effusions
statistically.Materials and methods
Pleural effusions
This study was conducted at the Chungnam National
University (South Korea). Effusion samples were collected
from the patients at Asan Medical Center (Seoul, Korea),
Konyang University Hospital (Daejon, Korea), or Chungnam
National University Hospital (Daejon, Korea). The samples
were obtained from 122 HIV-negative individuals: 81
samples were collected from TBP patients who were
diagnosed based on the histopathological discovery of
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positive M. tbc culture from biopsy specimens, and 41 were
diagnosed based on the discovery of malignant cells in
pleural fluid or pleural biopsy specimens in MP patients. The
study was reviewed and approved by the Institutional
Research Board of Chungnam National University Hospital,
and written informed consent was obtained from each
participant.
Preparation and purification of the mycobacterial
protein antigens
The MTB12 and 30-kDa antigens were purified from
M. tuberculosis H37Rv (ATCC27294) using the approach of
Lee et al.13 The native 38-kDa glycolipoprotein was purified
using the approach of Jung et al.14 Native antigens were
purified from the culture filtrate protein (CFP) of M. tbc
using sulfate precipitation, hydrophobic interaction chro-
matography, and anion-exchange chromatography, as de-
scribed previously.13,14
The recombinant HBHA was purified using the approach of
Shin et al.15 The pMV3-38 plasmid (pMV206-based construct)
containing the full-length HBHA open reading frame was
kindly provided by G. Delogu of the University of Sassari,
Sassari, Italy.17 ESAT-6 antigen was purified using the
approach of Sorensen et al.12 The pMRLB.7 plasmid
(pET23b-base construct) that contains the rESAT-6 protein
was a gift from P.J. Brennan and J.S. Spencer (Colorado
State University, CO, USA). Recombinant proteins were
expressed as NH2-terminal 6His-tagged fusion proteins
and were purified from Escherichia coli cells to near
homogeneity using metal chelate affinity chromatography.18
Cytokine ELISA
Cytokines in the pleural fluid samples were measured using
commercial ELISA kits according to the manufacturer’s
instructions: ELISA set (PharMingen, San Diego, CA) for
human IL-12p40, IFN-g, TNF-a, IL-6, IL-10, CXCL8/IL-8, and
CXCL10/IP-10 and Duo-Set (Genzyme, Cambridge, MA) for
CCL3/MIP-1a and CCL4/MIP-1b.
Antibody levels in the pleural effusions
The immunoglobulin G (IgG) and IgM antibody levels against
the antigens in pleural fluid from TBP and MP were
estimated. For indirect ELISA, polystyrene 96-well micro-
titer plates (Becton-Dickinson, USA) were coated overnight
at 4 1C with each of the five antigens mixed in carbonate–
bicarbonate buffer (0.015M, pH 9.5) at 1mg/ml (100ml/well).
For the mixed antigen complex, the single antigens were
mixed in the same buffer at 1 mg/ml. The plates were
washed three times with phosphate-buffered saline (PBS, pH
7.4) containing 0.05% (v/v) Tween 20 (PBS-T), blocked with
1% (w/v) bovine serum albumin (BSA) in PBS-T for 60min at
37 1C, and washed extensively with PBS-T. Pleural effusion
samples were diluted at 1:10 to 1:1000 for IgG and IgM in
PBS-T, and 100 ml of the diluted samples were added to the
antigen-coated wells. One well was used for each pleural
effusion sample. PBS-Twas added to the blank control wells.
The plates were then incubated for 2 h at 37 1C. The plateswere washed five times with PBS-T and then incubated for
1 h at 37 1C with 100 ml/well of horseradish peroxidase-
linked rabbit anti-human IgG and IgM conjugate (Sigma,
St. Louis, MO, USA). The plates were washed five times with
PBS-T, and 100 ml of TMB (BD Biosciences) substrate was
added to each well. After adding 50 ml of 1 N H2SO4 to stop
the reaction, the optical density (OD) at 450 nm was
measured using an ELISA plate reader (Microplate reader;
Bio-Rad, Richmond, CA).
Data analysis
Student’s t-test was used to compare the two groups; a p
value ofo0.05 was considered to be statistically significant.
Logistic regression analysis using backward stepwise method
was used to evaluate whether individual cytokine levels are
associated with tuberculous pleural effusion. Various cyto-
kine levels are transformed into categorical variables to use
independent variables in the logistic regression analysis of
the cytokines. In the logistic regression for antibody
responses against mycobacterial proteins, continuous vari-
ables are used as independent variables. Variables with P
values less than 0.05 in the univariate logistic regression
were fitted into a multiple logistic regression model.
Statistical analyses were conducted using the SPSS (Version
12.0) statistical software program (SPSS, Chicago, IL).
Results
Cytokine and chemokine responses in patients with
tuberculosis pleurisy or malignant pleurisy
The local T-cell response and the cytokine and chemokine
networks appear to be involved in the outcome of TBP and
may control the spread of M. tbc.4 Therefore, we examined
the cytokines and chemokines in pleural effusions from 41
patients with MP and 81 patients with TBP. To measure the
production of cytokines and chemokines over a logarithmic
range, we performed an ELISA with serially diluted super-
natants (1- to 100-fold). In the logistic regression, IFN-g
[odds ratio, 7.178; 95% confidence interval (CI),
2.258–22.817; p ¼ 0.001], IL-12 p40 (odds ratio, 11.037;
95% CI, 3.38–36.037; p ¼ 0.000), and IL-6 (odds ratio, 3.295;
95% CI, 1.147–9.463; p ¼ 0.027) were found to be statisti-
cally significant cytokines predicting tuberculous from
malignant effusions (Table 1). By contrast, there were no
significant differences in IL-10, CXCL8/IL-8, CCL3/MIP-1a,
and CCL4/MIP-1b production between the pleural effusions
from MP and TBP.
Humoral immune response to mycobacterial
antigens
Anti-mycobacterial antibody responses (IgG, IgM, and IgA)
were measured using an ELISA against M. tbc antigens (ESAT-
6, 30-kDa, MTB12, 38-kDa, and HBHA) in the pleural effusion
samples from TBP and MP patients. The humoral responses
to the mycobacterial antigens are summarized in Tables 2–4.
On detecting IgG- and IgM-specific antibodies, statistically
significant differences were found in the mean OD7S.D.
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Table 1 Logistic regression analysis for cytokine levels between tuberculous and malignant effusions.
Variables Odd ratio 95% CI p
Univariate analysis
IFN-g (pg/ml) (o402 vs. 402X) 16.128 5.658–45.973 o0.001
IL-12 p40 (pg/ml) (o481 vs. X481) 16.128 5.658–45.973 o0.001
IL-10 (pg/ml) (o194 vs. X194) 1.679 0.785–3.589 0.181
TNF-a (pg/ml) (o6 vs. X6) 2.535 1.161–5.535 0.02
IL-6 (ng/ml) (o15712 vs. X15712) 3.701 1.651–8.292 0.001
CXCL-8 (ng/ml) (o980 vs. X980) 1.247 0.587–2.647 0.556
CXCL-10 (pg/ml) (o367 vs. X367) 2.666 1.220–5.827 0.014
CCL3 (ng/ml) (o125 vs. X125) 1.953 0.909–4.199 0.086
CCL4 (ng/ml) (o66 vs. X66) 0.885 0.417–1.879 0.751
Multiple analysis
IFN-g (pg/ml) 7.178 2.258–22.817 0.001
IL-12 p40 (pg/ml) 11.037 3.38–36.037 o0.001
IL-6 (pg/ml) 3.295 1.147–9.463 0.027
CI, confidence interval.
Table 2 Comparison of IgG antibody responses against mycobacterial proteins between tuberculous and malignant effusions.
ELISA result for p valuey
MP (n ¼ 41) TBP (n ¼ 81)
Mean
OD7S.D.z
No. of
positive
samplesy
Specificity
(%)
Mean
OD7S.D.
No. of
positive
samples
Sensitivity
(%)
ESAT-6 0.5070.26 1 97.56 0.8670.35 29 35.80 6.20548E08
30-kDa 0.1570.25 2 95.12 0.4870.31 36 44.44 1.23848E07
MTB12 0.1170.13 2 95.12 0.4470.36 37 45.68 2.66734E07
38-kDa 0.0770.14 2 95.12 0.2270.18 23 28.40 1.24131E05
HBHA 0.1070.15 2 95.12 0.2670.18 18 22.22 8.5871E06
NS, not significant.
Pleural effusion were collected from both malignant pleurisy (MP) and TB pleurisy (TBP) patients and diluted 1:1000.
yFor statistic analysis, Student t-test was used to determine whether there were significant differences between the results of MP
and TBP.
zValues are expressed as means optical density (OD)7standard deviation (S.D.) at 450 nm.
yCutoff value for IgG antibodies to each antigen was calculated as the mean OD plus two S.D.
Immunoreactivities in Tuberculous Pleurisy 283between TBP and MP (Tables 2 and 3). In the anti-IgG
antibody response, the calculated cutoff values indicating a
difference between TBP and MP were 1.02, 0.66, 0.39, 0.34,
and 0.41 for ESAT-6, 30-kDa, MTB12, 38-kDa, and HBHA,
respectively (data not shown). The anti-IgG antibody
response to all of the antigens tested was significantly
higher in the TBP group than in the MP group (po0.001).
When the specificity and sensitivity of IgG against each
antigen were evaluated, MTB12 antigen had the highest
sensitivity (37/81, 45.68%) in TBP. However, similar sensi-
tivity was observed in the IgG responses to the 30-kDa
antigen (36/81, 44.44%) in TBP. The specificity of all of the
antigens was above 95.12% (Table 2). In the anti-IgM
antibody response, the calculated cutoff values indicating
a difference between TBP and MP were 0.24, 0.66, 0.36,
0.24, and 0.37 for ESAT-6, 30-kDa, MTB12, 38-kDa, andHBHA, respectively (data not shown). As shown in Table 3,
the anti-IgM antibody responses against ESAT-6, 38-kDa, and
HBHA were significantly higher in the TBP group (po0.01),
although the sensitivities of IgM against these antigens were
very poor. Nevertheless, IgM antibody had a specificity
exceeding 95.12% for all of the individual antigens (Table 3).
Of note, the HBHA antigen had the highest sensitivity of IgM
responses (25/81, 30.86%) in TBP. There was no statistically
significant difference in anti-IgA antibody for any of the
antigens tested (Table 4).
The logistic regression for antibody responses against
mycobacterial proteins showed IgG levels for ESAT-6 (odds
ratio, 10.721; 95% CI, 2.165–53.096; p ¼ 0.004) and MTB12
(odds ratio, 58.081; 95% CI, 4.184–806.25; p ¼ 0.002) to be
statistically significant for differentiating tuberculous from
malignant effusions (data not shown).
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Table 3 Comparison of IgM antibody responses against mycobacterial proteins between tuberculous and malignant effusions.
ELISA result for p valuey
MP (n ¼ 41) TBP (n ¼ 81)
Mean
OD7S.D.z
No. of
positive
samplesy
Specificity
(%)
Mean
OD7S.D.
No. of
positive
samples
Sensitivity
(%)
ESAT-6 0.1770.03 2 95.12 0.2070.04 14 17.28 0.0006
30-kDa 0.4670.09 0 100 0.4170.09 0 0 0.0022
MTB12 0.2070.07 2 95.12 0.2370.12 7 8.64 0.1948
38-kDa 0.1670.04 2 95.12 0.1870.04 9 11.11 0.0012
HBHA 0.1470.11 2 95.12 0.2870.16 25 30.86 1.44421E06
NS, not significant.
Pleural effusion were collected from both malignant pleurisy (MP) and TB pleurisy (TBP) patients and diluted 1:1000.
yFor statistic analysis, Student t-test was used to determine whether there were significant differences between the results of MP
and TBP.
zValues are expressed as means optical density (OD)7standard deviation (S.D.) at 450 nm.
yCutoff value for IgM antibodies to each antigen was calculated as the mean OD plus two S.D.
Table 4 Comparison of IgA antibody responses against mycobacterial proteins between tuberculous and malignant effusions.
ELISA result for p valuey
MP (n ¼ 41) TBP (n ¼ 81)
Mean
OD7S.D.z
No. of
positive
samplesy
Specificity
(%)
Mean
OD7S.D.
No. of
positive
samples
Sensitivity
(%)
ESAT-6 0.1170.06 2 95.12 0.0970.06 2 2.47 0.0601
30-kDa 0.1470.07 2 95.12 0.1470.09 8 9.88 0.8254
MTB12 0.1570.11 1 97.56 0.1670.34 3 3.70 0.7844
38-kDa 0.1170.06 3 92.68 0.0970.05 2 2.47 0.0878
HBHA 0.1870.15 1 97.56 0.1870.15 3 3.70 0.9653
NS, not significant.
Pleural effusion were collected from both malignant pleurisy (MP) and TB pleurisy (TBP) patients and diluted 1:1000.
yFor statistic analysis, Student t-test was used to determine whether there were significant differences between the results of MP
and TBP.
zValues are expressed as means optical density (OD)7standard deviation (S.D.) at 450 nm.
yCutoff value for IgA antibodies to each antigen was calculated as the mean OD plus two S.D.
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This study evaluated the differences in the cytokine,
chemokine, and antibody responses against five mycobac-
terial antigens in pleural fluids from TBP and MP patients, to
determine the diagnostic significance of these factors. Of
the cytokines, the IFN-g, IL-12p40, and IL-6 levels were
significantly elevated in pleural effusions from TBP com-
pared with those from MP (see Table 1), suggesting that
these cytokines would help to differentiate between MP and
TBP. The predominance of T-helper type 1 (Th1) immunity in
TBP was demonstrated by the high level of IFN-g in pleural
fluid,19 suggesting the important role of IFN-g in the localimmune response.20 Aoe et al.8 demonstrated that the
pleural effusion concentration of IFN-g is a useful diagnostic
marker for TB presenting as a lymphocytic exudative pleural
effusion. Our data are consistent with those studies
reporting a statistically higher level of pleural fluid IFN-g
in TBP in comparison with MP,7,8,19 suggesting that IFN-g can
be used as an alternative to conventional diagnostic
methods.
Several cytokines and chemokines have been identified as
critical factors in the interaction between sensitized
lymphocytes and infected macrophages during the initial
stages of infection. Studies have reported that TBP is a Th1-
dominant disease21 and that MP is a Th2-dominant disease.22
ARTICLE IN PRESS
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and are sufficiently activated to produce Th1 cytokines.23 It
has been reported that the concentrations of IFN-g-inducing
cytokines (IL-12 and IL-18), IFN-g, and IFN-g-inducible
chemokines such as IP-10 are all higher in tuberculous
pleural effusions than in malignant pleural effusions.24 IL-12
induces a Th1 response in undifferentiated CD4+ cells, and
this supports Th1 dominance at the morbid site of TB.25 In
addition, the pleural fluid TNF-a concentration was sig-
nificantly higher in tuberculous patients compared with non-
tuberculous patients.26 Another proinflammatory cytokine,
IL-6, was significantly elevated in the pleural fluids from
TBP, when compared with MP. In this study, the logistic
regression analysis suggests that IL-6, but not TNF-a, is
useful for differentiating between TBP and MP.
Although the role of antibody-mediated immunity in
protecting against M. tbc remains uncertain, exposure to
M. tbc elicits the production of antibodies to several
antigens, which could be used as markers of TB infec-
tion.27,28 Of the five most common classes of immunoglobu-
lins, IgG and IgM are usually examined in studies of TB
diagnosis through the detection of these antibodies in serum
and other body fluids using different single antigens. Our
data demonstrated that pleural fluids from TBP patients
produced significantly higher anti-IgG antibody responses to
individual antigens, compared with those from MP patients
(po0.001). The sensitivity of the IgG antibodies against
MTB12 (37/81, 45.68%) antigen was the highest to those
against other antigens. In addition, the logistic regression
for antibody responses shows that the IgG levels for ESAT-6
and MTB12 could distinguish TBP from MP statistically (Table
2 and data not shown).
MTB12 protein is secreted as a low-molecular-weight
protein antigen and is very abundant in M. tbc CFPs.29
Recently, we reported that the native MTB12 protein
strongly induced proinflammatory cytokines such as TNF-a
or IL-6, but not IFN-g, in human TB infection.13 The M. tbc-
specific ESAT-6 antigen induces potent T-cell responses and
IFN-g secretion by peripheral blood mononuclear cells in TBP
patients compared with healthy controls.30 Taken together,
both MTB12 and ESAT-6 antigens from M. tbc, may play a
possible role in the humoral immunity by inducing the IgG
antibody responses in TBP.
The ESAT-6, 38-kDa, 30-kDa, and HBHA antigens showed
significantly higher anti-IgM antibody responses in pleural
effusions from TBP compared with those from MP (po0.01).
The sensitivity of IgM against each antigen was poor, perhaps
because IgM is produced early in the course of the disease.31
As the onset of TBP is insidious, when patients seek medical
care, the switch to other immunoglobulin classes might
already have occurred. Nevertheless, our data emphasize
the role of HBHA antigen in the induction of IgM responses in
pleural effusions from TBP patients. HBHA is a M. tbc
adhesin molecule involved in the dissemination of the bacilli
from the site of primary infection.15 HBHA is a 28-kDa,
methylated, surface-exposed protein that mediates the
interaction of the tubercle bacilli with the host, acting as
an adhesion site for epithelial and endothelial cell layers.
Methylation of the C-terminal lysine residues affects both
the biochemical and immunological properties of the
protein.15,32 Several experimental findings have implicated
HBHA in the extra-pulmonary dissemination of M. tbc.15Previous studies have shown that purified methylated HBHA
was strongly recognized by sera obtained from TB patients,
compared with control sera.33 Recently, we also demon-
strated that the mean level and sensitivity of the anti-IgM
antibody to HBHA are significantly higher in the pooled sera
from TB patients compared with the sera from healthy
controls.15 Importantly, IgM antibody to HBHA might play a
role in protecting against extra-pulmonary dissemination.15
In the present study, we found that human IgM antibody
from TBP sera could effectively recognize rHBHA expressed
by Mycobacterium smegmatis but could not recognize rHBHA
expressed by E. coli (data not shown). Thus, methylated
HBHA antigen may play an essential role in the induction of
immunoreactivity during TB and TBP infection.
There was no statistically significant difference in anti-IgA
antibody levels against individual antigens, although IgA,
the predominant immunoglobulin in the mucosa/serosa
environment, is produced in the pleural space.34 Collec-
tively, our results indicate that the pleural fluid cytokine
concentrations (IFN-g, IL-12 p40, and IL-6), and mycobac-
terial antigens (ESAT-6 and MTB12, for IgG responses; HBHA,
for IgM responses) may be a potential marker for detecting
the development of TBP from MP. Further clinical studies
with larger sample sizes are necessary to validate these
tests in a routine clinical setting. Other antigens and host
factors should also be assayed to enhance the sensitivity of
the tests.
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